Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Global Blood Therapeutics
Age
45–80
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Documented diagnosis of IPF.
Oxygen desaturation with exercise.
Completion of the baseline 6MWT
Weight ≥ 50 kg
Male or female of child bearing potential willing and able to use highly effective methods of contraception from study start to 3 months after the last dose of study drug.
You may not be if
FEV1/FVC \< 70%.
Subjects on supplemental oxygen therapy at rest.
History of other interstitial lung diseases.
Significant polycythemia.
Female who is breast-feeding or pregnant.
Known current malignancy or history of malignancy within the last 2 years prior to screening.
Use of cytotoxic and/or immunosuppressant medications within 30 days screening.
Hospitalization due to an exacerbation of IPF within 30 days of screening
Subject plans to begin or has commenced pulmonary rehabilitation within 30 days of screening
Corticosteroids (\> 10 mg per day of prednisone or an equivalent) within 30 days of screening.
Current smoker or history of smoking within 3 months of screening.
Currently or, in the opinion of the investigator, soon to be listed for lung transplant.
History of unstable or deteriorating cardiac or pulmonary disease (other than IPF) within 6 months of screening.
Any condition possibly affecting drug absorption.
Participated in another clinical trial of an investigational drug (or medical device) within 30 days or 5-half-lives, whichever is longer, prior to screening, or is currently participating in another trial of an investigational drug (or medical device).
Subject who, for any reason, is deemed by the investigator to be inappropriate for this study.
Clareo Health | Study to Evaluate the Safety and Tolerability of GBT440 Administered to Subjects With IPF
